BMS turns to mechanistic diversity in early oncology pipeline

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces and technologies to see what sticks.

Now that the dust has settled on its 2019 acquisition of Celgene Corp., Bristol Myers Squibb Co. (NYSE:BMY) has to integrate the assets into its pipeline. It also has to work the series of deals it’s made since then and the investment in internal R&D into a portfolio that will yield revenue drivers as patent expirations for its top three sellers — Revlimid lenalidomide, Eliquis apixaban and Opdivo nivolumab — begin between one and eight years from now...